The drug, REC-994, was being tested to treat cerebral cavernous malformation, or abnormal collection of small blood vessels that form lesions in the brain, which could cause bleeding in the brain, seizures and paralysis.
The BTK inhibitor showed promise in non-relapsing secondary progressive multiple sclerosis but not relapsing MS. The company said it plans to apply for approval for the former “as soon as possible.”
Unlike Pfizer/BioNTech and Moderna, Novavax does not use mRNA technology for its COVID-19 vaccine, instead opting for a recombinant version of the virus’ spike protein to elicit protection.
Novo’s continuing supply problems for semaglutide come as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
U.S. gene sequencing company on Tuesday won its court fight against the European Union’s investigation of its $7.1 billion purchase of cancer diagnostic test maker Grail (GRAL.O), a ruling set to curb Brussels’ merger powers.
The U.S. government’s first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.